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Abstract
 Purpose—Utilization of sequencing to screen the general population for preventable 
monogenic conditions is receiving substantial attention due to its potential to decrease morbidity 
and mortality. However, the selection of which variants to return is a serious implementation 
challenge. Procedures must be investigated to ensure optimal test characteristics and avoidance of 
harm from false positive test results.
 Methods—We scanned exome sequences from 478 well-phenotyped individuals for 
potentially pathogenic variants in 17 genes representing 11 conditions that are among the most 
medically actionable Mendelian disorders in adults. We developed 5 variant selection algorithms 
with increasing sensitivity and measured their specificity in these 17 genes.
 Results—Variant selection algorithms with increasing sensitivity exhibited decreased 
specificity, and performance was highly dependent on the genes analyzed. The most sensitive 
algorithm ranged from 88.8% to 99.6% specificity among the 17 genes.
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 Conclusion—For very low prevalence conditions, small reductions in specificity greatly 
increase false positives. This inescapable test characteristic governs the predictive value of 
genomic sequencing in the general population. To address this issue, test performance must be 
evaluated systematically for each condition so that the false negatives and false positives can be 
tailored for optimal outcomes, depending on the downstream clinical consequences.
 INTRODUCTION
Screening programs can be valuable public health tools. Universal newborn screening has 
been highly successful in detecting severe but preventable genetic disorders. Such programs 
utilize defined mechanisms to select target conditions, based on their prevalence, severity, 
treatment options, and availability of a confirmatory test.1 Similar screening programs 
(based on genomics) may be emerging for the adult population, approximately 1% of whom 
are predisposed to a serious hereditary condition that may be preventable or ameliorated 
through early diagnosis.2 Large scale genomic sequencing initiatives comprising over 
100,000 people have been announced3,4 and screening of the general adult population for 
hereditary cancer has recently been proposed.5 President Obama also announced a U.S. 
initiative to recruit a cohort of one million people in order to advance the cause of “Precision 
Medicine,” echoing the UK’s effort to sequence whole genomes of 100,000 patients 
focusing on cancer and rare diseases. Finally, we are witnessing the emergence of direct to 
consumer companies marketing the opportunity for genomic screening to healthy 
individuals, thus potentially initiating a vast uncontrolled experiment in such an approach.
Human genetic variation is ubiquitous, with ~3 million nucleotide variants per individual 
genome. The vast majority of variants have no health implications, but certain rare variants 
cause heritable monogenic conditions. Some variants have undisputed pathogenicity in these 
disorders, whereas most have limited or no evidence of pathogenicity and all individuals 
have novel variants that are essentially “private” to their family. Importantly, many variants 
previously claimed as causal for monogenic disorders have conflicting assertions regarding 
pathogenicity, have been disputed by subsequent evidence,10-13 or have been determined to 
have less penetrance than other disease-causing variants in the same gene.14 Genetic variants 
identified in clinical sequencing are typically classified into 5 categories with respect to their 
etiologic role in monogenic disorders: Pathogenic, Likely Pathogenic, Uncertain 
Significance, Likely Benign, and Benign.15 The Pathogenic designation implies virtually 
complete certainty that the variant is causal for the disorder; however, there is no universal 
agreement on what “likely” means. One proposal suggested that the Likely Pathogenic 
designation should imply 95-99% confidence in the pathogenicity of the variant,16 but 
quantitating confidence in variant pathogenicity is difficult and few standardized methods 
exist.17 For most conditions there are no “gold standard” confirmatory tests that can 
adjudicate the pathogenicity of genetic variants.
In screening, the test performance (sensitivity and specificity) and the prevalence of the 
disorder determine the predictive value of a screen positive result. If genomic screening is 
misapplied in the general population, false positive results could lead to overtreatment, overt 
harm and monetary waste. Thus, it is imperative to understand the performance of 
sequencing and how to optimize thresholds for returning results in the novel context of 
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population screening, which are likely to be dramatically different than in a clinical 
diagnostic context.
Because of their low population prevalence, some monogenic disorders would require 
screening >10,000 people in order to detect a single true positive result. In such conditions, 
positive predictive value (PPV) is highly dependent on specificity, such that for a condition 
with 0.01% population frequency, reduction from 100% specificity to 99.94% specificity 
decreases PPV to 10%. This effect is similar but less pronounced in conditions with higher 
population frequencies. Although the technical sensitivity and technical specificity of 
sequencing (whether a genetic variant is truly present or not) can be measured relatively 
easily, there has so far been no effort to determine the clinical sensitivity or clinical 
specificity (whether the condition is truly present or not) of sequencing in the general 
population. Thus, it is completely unknown how genomic screening will fare in terms of 
predictive value.
The Center for Genomics and Society at the University of North Carolina at Chapel Hill is 
conducting an exploratory project, “GeneScreen,” to examine the feasibility and ethical 
considerations of screening 1,000 adults from the general population using massively 
parallel targeted sequencing of 17 genes responsible for 11 conditions that are among the 
most clinically actionable monogenic disorders in adults. A central obstacle to such 
screening is to clearly define criteria for variant selection and return, so as to avoid 
unacceptable numbers of false positives that would lead to unnecessary intervention and 
negative emotional, physical, or social consequences. Here, we evaluate different algorithms 
for selecting potentially pathogenic variants. The most stringent algorithm chooses variants 
that correspond closely to those that would be classified as “Pathogenic” in human review; 
the least stringent algorithm selects many additional variants that would be classified as 
having “Uncertain Significance.” We estimate the specificity of these algorithms in 478 
exomes from a diverse cohort of well-phenotyped participants in a separate clinical 
sequencing exploratory research project, allowing us to simulate expected findings in the 
general population. This represents the first attempt to empirically measure the performance 
of genomic sequencing for population screening.
 SUBJECTS AND METHODS
 Exome sample
Exome data from 478 participants in the IRB-approved North Carolina Clinical Genomic 
Evaluation by Next-gen Exome Sequencing (NCGENES) project were analyzed for the 17 
GeneScreen genes (APC, BRCA1, BRCA2, HFE, FBN1, KCNH2, KCNQ1, LDLR, MLH1, 
MSH2, MSH6, MUTYH, PMS2, RET, RYR1, SCN5A, SERPINA1). The NCGENES 
participants were previously sequenced in a diagnostic context for a variety of phenotypes, 
including cancer, aortic aneurysm, and arrhythmia (manuscript in preparation). Any 
participants who were sequenced for a primary indication overlapping with a condition 
described in this manuscript were excluded from the analysis for those conditions. Exome 
variants were loaded into a PostgresSQL database (v.9.0.3) for annotation and facilitation of 
queries.18
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 Variant selection and specificity calculations
Variants classified as pathogenic or likely pathogenic in the National Center for 
Biotechnology Information ClinVar database19 (downloaded 2/14) and variants labeled as 
“DM” (Disease Mutation) in the Human Gene Mutation Database20 (HGMD; 2014, v2) 
were collected as a source of potentially pathogenic variants. Recognizing that many 
variants in these databases may be erroneously classified, variants were excluded if 
pathogenicity assertions were discordant.
Population allele frequency estimates were determined using the Exome Aggregation 
Consortium (ExAC), a resource composed of 63,358 unrelated individuals sequenced 
through a variety of studies.21 Each gene was analyzed using one of three different minor 
allele frequency thresholds: 1%, 0.1%, or 0.01%. The minor allele frequency threshold 
chosen for each gene was based on the maximum expected population frequency of 
pathogenic alleles for the associated condition. In addition, variants in genes associated with 
conditions having dominant inheritance were eliminated if the minor allele frequency in the 
exome sample was >0.5%. CADD scores22 were retrieved for novel missense variants, with 
a Phred score of 13 as the threshold for deleteriousness. Conserved functional domains 
within proteins were obtained from the RefSeq database.23
Five variant selection algorithms (VSA1-5) were applied to the 17 genes, with each 
successive algorithm choosing more potentially pathogenic variants that could qualify as a 
“positive” screening result:
• VSA-1 includes rare variants classified as “Pathogenic” in ClinVar. Many (but 
not all) of these variants would be considered “Pathogenic” in human review.
• VSA-2 adds rare predicted truncating variants (nonsense, frameshift, canonical 
splice-site). These additional variants would largely be considered “Likely 
Pathogenic” in human review.
• VSA-3 adds rare variants classified as “Likely Pathogenic” in ClinVar and/or 
as a “Disease Mutation (DM)” in HGMD. Many of these variants would be 
considered “Likely Pathogenic” or to have “Uncertain Significance” in human 
review.
• VSA-4 adds rare missense variants with CADD scores >13 that are located 
within a conserved functional domain. Most of these variants would be 
considered to have “Uncertain Significance” in human review.
• VSA-5 adds all rare missense variants, regardless of CADD score or location. 
Most of these variants would also be considered to have “Uncertain 
Significance”.
The algorithms take into account zygosity, such that either a homozygous variant or two 
potentially biallelic variants were required for a “positive” screen in MUTYH, HFE, and 
SERPINA1.
While each successive algorithm is expected to have increased sensitivity, the actual 
sensitivity cannot be directly measured in this cohort because we excluded participants with 
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phenotypes overlapping these conditions. Given the rarity of the conditions being evaluated, 
we do not expect to find truly affected individuals for most of the disorders. Therefore, the 
number of true positives in the sample should be between 0-1 for most conditions, even 
including non-penetrant alleles. For estimated specificity calculations, we assumed that all 
“positive” screening results in this small sample were false positives, with the exception of 
certain variants with undisputed pathogenicity after curation of results from VSA-1 and 
VSA-2 (eg., HFE C282Y, Ashkenazi founder mutations in BRCA1 and BRCA2). Specificity 
estimates were adjusted and confidence intervals were calculated using the Wilson score 
interval.24
 RESULTS
The GeneScreen project has identified 17 genes implicated in 11 monogenic disorders that 
are expected to be highly actionable in the adult population, in which to explore genomic 
screening in the general population. We simulated the performance of genomic screening of 
these genes in the general population by applying five algorithms for identifying potentially 
pathogenic variants in 478 exomes (Figure 1). VSA-1, which includes only variants 
classified as “pathogenic” in ClinVar, has the lowest sensitivity of the algorithms tested and 
returned the fewest variants overall, with specificity expected to approach 100% in ideal 
testing conditions if results are restricted to unquestionably pathogenic variants. Even so, 
some variants currently listed in ClinVar as “pathogenic” are not definitively pathogenic and 
thus the specificity of VSA-1 was 99.5%. The overall specificity of VSA-2 was also 99.5% 
and the overall specificity of VSA-3 was 99.4%. As expected, the most sensitive algorithms, 
which include rare missense variants, had the lowest specificity: VSA-4 had an overall 
specificity of 98.7%, and VSA-5 had an overall specificity of 97.1%. This demonstrates that 
the increased sensitivity afforded by inclusion of missense variants results in a concomitant 
decrease in overall specificity and hence would result in a substantial increase in false 
positive results.
However, it is more important to consider the performance of the algorithms with respect to 
each gene. Two individuals were homozygous for the HFE C282Y pathogenic variant, and 
another two individuals were homozygous for the SERPINA1 pathogenic variant that results 
in the “Pi-Z” Alpha-1 Antitrypsin deficiency phenotype. These findings are interpreted to be 
“true positives” since their pathogenicity is undisputed. Two of the genes with very low 
prevalence (MUTYH and RET) had no “positive” screening results identified by any 
algorithm. Most of the genes had very few “positive” results identified by either VSA-1 or 
VSA-2, indicating that increasing the sensitivity of the algorithm by including rare predicted 
truncating variants does not dramatically reduce specificity. VSA-3 (which includes variants 
classified in ClinVar as “likely pathogenic” or HGMD as “disease mutations”) identified 
numerous “positive” results in several genes, including BRCA1, BRCA2, KCNQ1, LDLR, 
and RYR1, consistent with the well-established concern of misclassification of variants in 
current reference databases and highlighting the need for databases with high quality lists of 
pathogenic variants. Finally, a large number of “positive” results were identified in most 
genes by the more sensitive algorithms, VSA-4 and VSA-5, reflecting higher underlying 
variation in certain genes that could impose an upper limit on the possible clinical sensitivity 
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of genomic screening in order to preserve specificity. The performance of the variant 
selection algorithms for each gene was plotted as 1-specificity (Figure 2).
 DISCUSSION
This study models genomic screening of 17 genes for 11 highly actionable monogenic 
disorders and demonstrates the tradeoff between sensitivity and specificity among variant 
selection algorithms that might be used in a large-scale screening program. Genomic 
screening of the general population differs significantly from the much more familiar pursuit 
of diagnostic genomic sequencing because a symptomatic patient has a much higher pre-test 
probability of having a pathogenic variant than the average individual in the general 
population. We have evaluated informatics algorithms that can be used to screen genomic 
data for potentially pathogenic variants, and for the first time attempted to measure the 
specificity of genomic findings in the context of population screening.
For most conditions, the true clinical sensitivity of genetic testing is not well established. In 
some cases, a very small number of variants account for a high proportion of cases and thus 
sensitivity of the most stringent variant selection algorithms will be high, whereas in other 
conditions a high proportion of cases are due to novel or private mutations that would not be 
documented in databases of known pathogenic variants, thus reducing the sensitivity of the 
most stringent variant selection algorithms. In most conditions it is very difficult to discern 
what fraction of cases are caused by recurrent mutations (which would be considered 
“known pathogenic”) versus novel or rare mutations that may only occur in a small fraction 
of cases (which might be considered “likely pathogenic”). That being said, the predictive 
value of a sequencing-based screening test for rare monogenic disorders hinges 
predominantly on specificity, not sensitivity.
 The relationship between variant pathogenicity and test specificity
We suggest that the degree of confidence regarding variant pathogenicity is analogous to the 
specificity of that result. Tests reporting only “Pathogenic” variants approach 100% 
specificity, whereas tests reporting “Likely Pathogenic” variants have 90-95% specificity 
depending on the confidence standard applied. In the diagnostic context, reduced specificity 
is acceptable because of the high pre-test probability and the importance of excluding a 
diagnosis, when possible. However, when screening the general population for rare 
conditions, even a small decrease in specificity has a devastating impact on PPV. Conversely, 
in the case of rare conditions NPV is not significantly improved by even large changes in 
sensitivity, which decreases the imperative to consider novel variants that inherently reduce 
the specificity of the screening test. These factors are critical points to consider in the design 
of genomic screening algorithms for the healthy population.
For example, the prevalence of three BRCA1 and BRCA2 pathogenic founder mutations in 
the Ashkenazi Jewish population is 2.6%25 and the specificity for these variants is 100%, 
resulting in a very high PPV. However, the specificity of most other variants (including novel 
truncating variants) will be less than 100%. In the general population, where disease 
prevalence is less than 1% and a much wider range of pathogenic variants is detected,26 a 
decrease of specificity to even 99% would result in a PPV of 37%, which some may find 
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unacceptable for application of such screening in the general population. This dramatic 
decrease in PPV, despite a very small change in specificity, is true for all rare monogenic 
conditions.
It should be noted that fully automated analysis of results without some level of human 
curation prior to confirmation and reporting is not possible at present; thus variants flagged 
as a possible “positive” screening result by informatics algorithms are expected to undergo 
scrutiny by a human analyst to further reduce reporting of clearly non-pathogenic variants. 
This necessity for some level of human curation will be a critical limiting factor for 
deployment of genomics in large-scale population screening but can be optimized by 
designing variant selection algorithms that maximize the sensitivity of the screen without 
burdening the reviewer with numerous non-pathogenic variants. In the long term, the 
empiric sensitivity and specificity of variant selection algorithms may be a more accurate 
measure of predictive value than the pathogenicity classifications used in diagnostic testing.
 Balancing outcomes, interventions, and the implications of screening results
The conditions being evaluated in the GeneScreen project are heterogeneous with respect to 
the penetrance, expressivity of manifestations, and recommended follow-up management 
strategies (Table 1). Positive genomic screening results in these conditions would lead to 
increased clinical surveillance and other interventions. In the case of pathogenic variants in 
BRCA1 or BRCA2, management options include increased surveillance or prophylactic 
mastectomy and/or bilateral salpingoophorectomy. These recommendations are very 
different from management of Familial Hypercholesterolemia due to pathogenic variants in 
LDLR, which includes periodic monitoring of cholesterol and treatment with cholesterol-
lowering medications, an efficacious intervention with dramatically less impact (physical, 
psychosocial and monetary). Thus, the downstream consequences of positive screening 
results will differ between conditions. It should be noted that in conditions with incomplete 
penetrance, even truly pathogenic variants may not manifest in disease and therefore would 
constitute overdiagnosis in some individuals who would not develop disease in their lifetime. 
This concern is similar in many ways to a false positive result, in that the downstream 
consequences would not be expected to benefit these individuals and would only expose 
them to harm.
The negative consequences of genomic screening can be minimized if any of the following 
conditions exists: 1) test performance maximizes PPV and thus results in few false positives, 
2) low-risk confirmatory follow-up tests can reduce the number of false positives, or 3) 
downstream consequences of false positives are relatively insignificant. Thus, a genomic 
screening project could consider customizing PPV thresholds for different conditions based 
on the above criteria and available information about the mutational spectrum and proportion 
of cases attributable to known versus novel mutations (Table 1). For example, for BRCA1 or 
BRCA2 the false positive rate will need to be very low, because risk-reducing surgery is an 
important management step and no confirmatory tests exist to ensure that a genetic variant is 
indeed pathogenic. Thus, only carefully curated lists of pathogenic variants and, perhaps, 
rare truncating variants (the equivalent of VSA-2) should be reported in a screening context. 
In other cases, inclusion of rare, potentially damaging missense variants (VSA-4) may be 
Adams et al. Page 7
Genet Med. Author manuscript; available in PMC 2016 July 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
acceptable, depending on the specificity of variant selection algorithms for the gene, the 
spectrum of pathogenic mutations observed, and the false positive tolerance based on 
clinical implications of a positive screening result.
The argument that population genomic screening should utilize gene-specific false positive 
thresholds requires precise measurement of the clinical sensitivity and clinical specificity of 
variant selection algorithms (as well as the prevalence of the condition) in order to optimize 
PPV. However, such estimates will likely require a dataset of 100,000+ individuals with 
extensive phenotypic data, which does not yet exist, and the specificity estimates provided 
here should be considered provisional. The population being sequenced also needs to be 
considered – existing datasets fail to comprehensively ascertain the pathogenic and benign 
variants that are present in diverse populations, which will impact variant selection 
algorithms and pathogenicity assessments. In addition, databases of clinically relevant 
variants are known to have entries with misattributed pathogenicity, and will need to be 
greatly improved before they can be relied upon for screening.
 Conclusions and Future Directions
Screening the general population for deleterious variants in highly selected genes holds great 
promise to decrease morbidity and mortality for millions of individuals. However, we must 
be cognizant of our limited ability to interpret the pathogenicity of rare genomic variation, 
the implications this has for standards used to analyze and report genomic findings, and the 
downstream consequences of screening in the general population. Otherwise, great harm 
could result. Much additional research is required to assess the overall cost of screening 
efforts, including the downstream effects of false positive tests, in order to evaluate the 
overall economic impact of genomic screening.27 A host of factors will need to be studied, 
including cost-effectiveness, adverse consequences of interventions, insurance impact, 
education and consent materials that address the complexity of potential harms and benefits 
of screening, implications for reproductive choices, potential psychosocial impacts, and the 
benefits and harms of familial cascade testing.
In this study we have addressed a small subset of highly actionable genetic conditions, that 
we think are currently the most promising candidates for genomic screening in the general 
adult population. However, these results also have fundamental implications for any effort 
that considers genome-scale sequencing in healthy individuals. Although genomic 
sequencing is inherently appealing for personalized medical care, it should be initiated 
cautiously with rigorous attention to the predictive value of genetic variation, and with 
careful consideration of the implications of false positive results across the broad range of 
genetic conditions that could potentially be identified.
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Figure 1. Yield of potentially pathogenic variants using variant selection algorithms with varying 
sensitivity
Five variant selection algorithms with different degrees of sensitivity and specificity were 
constructed. VSA-1 is the least sensitive algorithm and most specific, because it only 
considers a subset of variants previously defined as pathogenic. VSA-5 is the most sensitive 
but least specific, considering all rare truncating and missense variants (most of which would 
be considered “variants of uncertain significance”) to constitute a positive screen. These 
algorithms were applied to exome sequence data from 478 individuals in order to 
empirically evaluate the yield of possibly pathogenic variants in the 17 genes selected for 
population screening. The number of people who would screen positive per 1000 individuals 
screened is displayed on the vertical axis, with each gene along the horizontal axis, for all 
variant selection algorithms.
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Figure 2. False Positive Rate estimates of variant selection algorithms in 17 medically actionable 
genes
Specificity estimates were calculated for five variant selection algorithms for screening of 17 
genes using exome data from 478 well-phenotyped individuals. The variant selection 
algorithm label is displayed on the vertical axis and the associated false positive rate (1-
specificity) is plotted on the horizontal axis, for each graph in the panel.
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